Omeprazole vs
Pro Research Analysisby 
Searched over 200M research papers for "omeprazole vs"
Comparative Efficacy and Safety of Omeprazole in Gastrointestinal Disorders
Omeprazole vs. Placebo in Gastric Ulcer Treatment
Omeprazole, a proton pump inhibitor, has been extensively studied for its efficacy in treating benign gastric ulcers. A multicenter, randomized, double-blind study involving 520 patients compared the effects of omeprazole (40 mg and 20 mg) with a placebo over 4 to 8 weeks. The results demonstrated that both doses of omeprazole significantly outperformed the placebo in healing ulcers. Specifically, the 40 mg dose was more effective than the 20 mg dose, particularly in patients with larger ulcers (>1 cm)1.
Omeprazole vs. Esomeprazole in GERD with Erosive Esophagitis
In patients with gastroesophageal reflux disease (GERD) and erosive esophagitis, esomeprazole (40 mg) has shown superior efficacy compared to omeprazole (20 mg). A large-scale study with 2425 patients revealed that esomeprazole had higher healing rates at both 4 and 8 weeks and provided better symptom relief, including heartburn resolution. Both medications had similar safety profiles, with common adverse events being headache, diarrhea, and nausea2.
Omeprazole vs. Ranitidine in Preventing Esophageal Stricture Recurrence
A study comparing omeprazole (20 mg once daily) and ranitidine (150 mg twice daily) in preventing the recurrence of benign esophageal stricture post-dilatation found omeprazole to be more effective. Patients on omeprazole required fewer redilatations and experienced better symptom relief, with a higher percentage being free of dysphagia and able to maintain a normal diet4.
Omeprazole vs. Rabeprazole in GERD Treatment
A European multicenter study compared the efficacy of rabeprazole (20 mg) and omeprazole (20 mg) in treating erosive or ulcerative GERD. Both medications showed equivalent healing rates at 4 and 8 weeks, with similar relief in heartburn frequency and intensity. The safety profiles of both drugs were comparable, with no significant differences in laboratory parameters or adverse events7.
Omeprazole vs. Pantoprazole in Intragastric pH Control
Pantoprazole (40 mg) has been found to be more effective than omeprazole (20 mg) in increasing intragastric pH over a 24-hour period. This was observed in both single and repeated doses, with pantoprazole achieving steady-state serum concentrations more rapidly. Both medications were well tolerated, with no significant changes in vital signs or clinical laboratory parameters10.
Conclusion
Omeprazole is a highly effective treatment for various acid-related gastrointestinal disorders, including gastric ulcers, GERD, and esophageal strictures. It generally outperforms placebo and is comparable or slightly less effective than some newer proton pump inhibitors like esomeprazole and pantoprazole. Omeprazole also shows superior efficacy compared to H2-receptor antagonists like ranitidine. Its safety profile is well-established, making it a reliable option for long-term management of acid-related conditions.
Sources and full results
Most relevant research papers on this topic
Comparison of once-daily doses of omeprazole (40 and 20 mg) and placebo in the treatment of benign gastric ulcer: a multicenter, randomized, double-blind study.
Omeprazole 40 and 20 mg once daily effectively healed more benign gastric ulcers than placebo, with the 40-mg regimen showing significant advantages in patients with large ulcers.
RCT
Large Human TrialEfficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial
Esomeprazole is significantly more effective than omeprazole in treating erosive esophagitis in GERD patients, with comparable tolerability and safety.
RCTLarge Human Trial
Highly CitedTwo doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study.
Omeprazole 20 or 40 mg doses effectively treat erosive esophagitis and provide complete relief of heartburn symptoms, with higher doses providing better healing and relief.
RCTHighly CitedA comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Restore Investigator Group.
Omeprazole, 20 mg once daily, is more effective than ranitidine in preventing recurrence of benign esophageal stricture and providing symptom relief.
RCTLarge Human TrialHighly CitedOmeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.
Omeprazole is a well-tolerated and well-tolerated acid pump inhibitor for treating various acid-related disorders, with rapid healing and minimal relapse rates.
Literature ReviewHighly CitedOmeprazole before endoscopy in patients with gastrointestinal bleeding.
Infusion of high-dose omeprazole before endoscopy accelerated the resolution of bleeding in ulcers and reduced the need for endoscopic therapy in patients with gastrointestinal bleeding.
RCTLarge Human TrialHighly CitedDouble-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
Rabeprazole 20 mg once daily and omeprazole 20 mg once daily both effectively treat erosive or ulcerative gastro-oesophageal reflux disease, with similar heartburn relief and well-tolerated outcomes.
RCTHighly CitedOmeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice.
Omeprazole, 20 mg, is the most effective initial therapy for relief of gastro-oesophageal reflux disease symptoms.
RCTLarge Human TrialHighly CitedOmeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.
Omeprazole is effective in treating Helicobacter pylori infection, gastro-oesophageal reflux disease, and gastrointestinal damage caused by nonsteroidal anti-inflammatory drugs, with potential for triple therapy regimens.
Literature ReviewHighly CitedTwenty‐four‐hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole.
Pantoprazole 40 mg is significantly more effective than omeprazole 20 mg in raising intragastric pH, with steady-state serum concentrations achieved after the first dose.
RCTHighly Cited